Point-of-care testing

Global Innovators Converge for the 16th Annual Lab-on-a-Chip and Microfluidics Europe 2024 Conference - ResearchAndMarkets.com

Retrieved on: 
Montag, Juni 10, 2024
Research, Technology, Semiconductor, Health Technology, Nanotechnology, Biotechnology, General Health, Pharmaceutical, Health, Science, Seminal vesicles, Imperial College London, Biofabrication, University of Groningen, Plasmonics, LOAC, Point-of-care testing, Biosensor, Printing, Professor, Engineering, University, 3D, Organoid, CNRS, 3D bioprinting, Biomarker, Biomedical engineering, Business development, Exhibition, Translational research, Biochemistry, Analytical chemistry, Video game

The "Lab-on-a-Chip and Microfluidics Europe 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lab-on-a-Chip and Microfluidics Europe 2024" report has been added to ResearchAndMarkets.com's offering.
  • The esteemed Lab-on-a-Chip and Microfluidics Europe 2024 conference is scheduled to take its 16th year by storm, presenting a unique convergence of academia and industry professionals dedicated to advancements in LOAC and microfluidics.
  • The day day Lab-on-a-Chip and Microfluidics Europe 2024 conference takes place in Rotterdam, Netherlands, on June 24-25th, 2024.
  • In a synergistic format, registered delegates will gain full access to co-located conferences, including Point-of-Care, Biosensors & Mobile Diagnostics Europe 2024; Organoids and Spheroids Europe 2024; and Circulating Biomarkers and Extracellular Vesicles Europe 2024.

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Retrieved on: 
Freitag, Juni 14, 2024
POCT, PCR, Patient, RSV, Point-of-care testing, Tuberculosis, Infection, COVID-19, Influenza, POC, FDA, Sale, Food, OTC, Diagnosis, Medical device

SALT LAKE CITY, June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has completed its first U.S. Food and Drug Administration (FDA) application for 510(k) clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter (OTC) use.

Key Points: 
  • Co-Diagnostics completed the submission via the FDA's electronic Submissions Template And Resource (eSTAR) system, and have received the acknowledgement from the FDA that the 510(k) application was received.
  • The Co-Dx PCR platform has been designed to help close the access gap for infectious disease diagnosis by facilitating the widespread decentralization of gold-standard PCR diagnostics, which have historically only been found in high-complexity clinical laboratories.
  • *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

UAE In-Vitro Diagnostics Devices Market Report 2024-2032: Government Investments in Healthcare Infrastructure, Prevalence of Chronic Diseases Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Montag, Mai 13, 2024
Biotechnology, Health Technology, Health, Medical Devices, Diabetes, Application, USB On-The-Go, Point-of-care testing, Investment, Prevalence, Conditional sentence, Medical tourism, Diagnosis, Urine, Government, Microbiology, Disease, Safety, Notifiable disease, Ageing, Blood, Urbanization, Growth, Cancer, Environment, IVD, Medical device

The "UAE In-Vitro Diagnostics Devices Market Report by Application, End-User 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "UAE In-Vitro Diagnostics Devices Market Report by Application, End-User 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The robust government healthcare investments fostering advanced technologies and the escalating prevalence of chronic diseases demanding accurate diagnostics for effective management are among the key factors driving the market growth.
  • The UAE government's substantial investments in healthcare infrastructure are a pivotal driving force behind the growth of the IVD devices market.
  • The increasing prevalence of chronic diseases, exacerbated by changing lifestyles, is a significant driver of the UAE's IVD devices market.

Autoimmune Disease Diagnostics Market Research, Size, Global Forecasts 2024-2030: Robotics and AI, Autoantibody Assays and Genetic Testing, & Innovative Biomarkers Drive Expansion - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, Mai 9, 2024
Robotics, Medical Devices, Health, Technology, Health Technology, Artificial Intelligence, Mortality, Diagnosis, AI, Prognosis, Research, Heart, Diabetes, Insurance, SADS, Genetic testing, Point-of-care testing, Automation, Autoimmune disease, Arthritis, Patient, Inflammatory bowel disease, Rheumatoid arthritis, Physician, Consciousness, Arthritis Foundation, Lupus, Biomarker, Wipro, Multiple sclerosis, Disease, Vaccine

The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.

Key Points: 
  • The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.
  • By product, the global autoimmune diseases diagnostics market is fragmented into Therapeutic & Monitoring Equipment, Diagnostics Equipment, and Drugs.
  • The global autoimmune diseases diagnostics market is segmented into Systemic Autoimmune Disease Diagnostics and Localized Autoimmune Disease Diagnostics.
  • By indication, the global autoimmune diseases diagnostics market is categorized into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Others.

Global Legionella Testing Market Analysis 2024-2029: Global Legionella Testing Market Surges to US$514.9 Million by 2029 - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Mai 7, 2024
Infectious Diseases, Health, Other Health, Public, Internet of things, Element, Pneumonia, Polymerase chain reaction, Urbanization, Point-of-care testing, PCR, Risk management, Application, Ageing, COVID-19, Growth, Compound annual growth rate

The "Global Legionella Testing Market: Analysis By Type, By Application, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Legionella Testing Market: Analysis By Type, By Application, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The global legionella testing market has shown impressive growth, with its value reaching US$315.08 million in 2023, and projections suggest an ascent to US$514.9 million by the year 2029.
  • A geographic spotlight on the legionella testing market reveals North America's dominance due to strict water safety stipulations and advanced healthcare infrastructure.
  • The global legionella testing market anticipates a surge in technological advancements and an increased adoption of preventive measures.

The Market and Future Potential for Molecular Point-of-Care (mPOC) Report, 11th Edition, with Profiles of 30+ Key Industry Players - ResearchAndMarkets.com

Retrieved on: 
Mittwoch, April 10, 2024
General Health, Infectious Diseases, Biometrics, Health, Medical Supplies, Cepheid variable, Clinic, Molecule, Forecasting, Point-of-care testing, PCR, BioMérieux, Patient, Microbiology, Market, POC, COVID-19, IVD, Growth, Row

The "Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition" report has been added to ResearchAndMarkets.com's offering.
  • Molecular point-of-care (mPOC) diagnostic solutions offer enhanced sensitivity and specificity compared to existing near-patient and rapid tests.
  • The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition, is a valuable resource for understanding the size and growth potential of the molecular POC market from 2023-2028. mPOC has transitioned from a novel trend to a significant contributor to the market.
  • What's the size of the Molecular Point-of-Care Market: 2023-2028
    Geographic Breakout of the Molecular Point-of-Care Market, 2023 (N. America, Europe, APAC, RoW)
    Segment Breakout of Molecular Point-of-Care Market, 2023 (Respiratory vs. Other)
    Near Patient Molecular IVD Market: 2023-2028
    Near Patient Molecular Market Share by Vendor, 2023
    Companies covered in this report, in profiles and/or product tables and market developments discussion include:

SCOUT RECEIVES FUNDING FROM CARB-X TO DEVELOP A LOW-COST POINT-OF-CARE AND HOME DIAGNOSTIC FOR GONORRHEA AND CHLAMYDIA

Retrieved on: 
Donnerstag, April 18, 2024
Chlamydia trachomatis, FDA, Mortality, Administration, Pelvic inflammatory disease, Malaria, Death, Doctor of Philosophy, Vaccine, Development, Point-of-care testing, PHAC, Diagnosis, Gonorrhea, Novo Nordisk Foundation, Prevalence, HHS, Vertical loop, Neonatal sepsis, Infertility, OTC, Public Health Agency, Entrepreneurship, Infection, Urine, Neisseria gonorrhoeae, Patient, Ng, CARB-X, NIH, Education, BMBF, STI, Therapy, Disease, Bangladesh Technical Education Board, SARS-CoV-2, HIV/AIDS, Social work, NIAID, Bill, Physician

BOSTON, April 18, 2024 /PRNewswire/ -- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1 million to diagnostics and health tech company Scout to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test – STI Scout. The test will detect and differentiate between Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.

Key Points: 
  • STI Scout is quick and inexpensive, with a turnaround time of 30 minutes and costs anticipated to be less than half of other options.
  • Additionally, STI Scout can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility.
  • STI Scout uses the Scout Hub to run and the Scout Connect mobile app, which provides instructions, tracks results, and eventually will allow patients to connect digitally to a healthcare provider.
  • Scout's diagnostic is the second diagnostic and ninth project to receive a CARB-X award as part of the 2022-2023 funding call .

Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%

Retrieved on: 
Montag, März 18, 2024
Cloud, Research, SKQ1, Quality control, Weather, NMPA, Therapeutic Goods Administration, Environment, Best, Intelligence, Patent, Patient, Conditional sentence, Ophthalmology, Hospital, POCT, Acquisition, CMC, European Medicines Agency, GMP, City, QMS, Bevacizumab, Chemistry, Yoy, US FDA, Traction, Good, Therapy, Point-of-care testing, VISTA, Pharmaceutical industry

The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.

Key Points: 
  • The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.
  • As of 31 December 2023, the Group had cash and cash equivalents of approximately HK$509.8 million (2022: approximately HK$543.5 million).
  • Together with the interim dividend of HK$0.045 per ordinary share paid on 13 September 2023, the total dividend for 2023 would be HK$0.09 (2022: HK$0.065) per ordinary share.
  • The Group's turnover is primarily made up of the ophthalmology segment ("Ophthalmology") and surgical (wound care and healing) segment ("Surgical").

HealthTab™ Signs Agreement for More Rexall® Pharmacy Locations

Retrieved on: 
Donnerstag, April 4, 2024
Rexall, Patient, Pharmacist, Workflow, OTC, ID, Point-of-care testing, Pharmaceutical industry

The Companies have been working closely to develop the best patient approaches and internal workflows to ensure the most successful deployment of this powerful point-of-care testing platform.

Key Points: 
  • The Companies have been working closely to develop the best patient approaches and internal workflows to ensure the most successful deployment of this powerful point-of-care testing platform.
  • “To successfully screen and manage chronic and infectious disease, healthcare systems need pharmacists to play an active role,” said Hector Bremner, CEO of Avricore Health.
  • The next steps will be to deploy a minimum of another 20 locations spread out between stores in Alberta and Ontario.
  • After each deployment, the teams will collaborate to assess deployment workflow, refine processes and identify further deployment opportunities based on patient and pharmacist feedback.

Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address

Retrieved on: 
Donnerstag, März 21, 2024
PCR, Bill, Tuberculosis, World Tuberculosis Day, Incidence, COVID-19, Sale, Death, World Health Organization, TB, Point-of-care testing, FDA

SALT LAKE CITY, March 21, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that in his keynote address at the 5th Annual MarketsandMarkets conference in London, Company CEO Dwight Egan shared an update on the new manufacturing facilities in Salt Lake City, Utah and in Ranoli, India, including announcing the grand opening of the new Utah facility next month.

Key Points: 
  • Both Co-Dx and CoSara Diagnostics, the Company's joint venture for manufacturing in India, will be manufacturing the Co-Dx™ PCR Pro™ instrument and Co-Dx PCR test cups that run on the Company's new PCR platform*.
  • In-house manufacturing of the reagents as well as equipment and consumables is anticipated to play an important role as the Company prepares for commercialization of its new platform.
  • The estimated TB incidence rate in India alone was 2.82 million , leading to nearly 350,000 deaths for the year.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.